MedTrace Logo

Treatment With Copper in Patients With Mild Alzheimer´s Dementia

NCT00608946 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2008-02-06

No results posted yet for this study

Summary

The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild Alzheimer´s dementia.

Conditions

  • Alzheimer´s Disease

Interventions

DIETARY_SUPPLEMENT

copper

intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status

DIETARY_SUPPLEMENT

placebo

placebo

Sponsors & Collaborators

  • University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany

    collaborator OTHER

  • University Hospital, Saarland

    lead OTHER

Principal Investigators

  • Frank G Pajonk, M.D., lecturer · Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608946 on ClinicalTrials.gov